Last reviewed · How we verify
Lidocaine patch 1.8%
Lidocaine blocks sodium channels in nerve fibers, interrupting pain signal transmission at the site of application.
Lidocaine blocks sodium channels in nerve fibers, interrupting pain signal transmission at the site of application. Used for Postherpetic neuralgia (PHN), Localized neuropathic pain.
At a glance
| Generic name | Lidocaine patch 1.8% |
|---|---|
| Also known as | Lidocaine topical system 1.8%, ZTlido |
| Sponsor | Scilex Pharmaceuticals, Inc. |
| Drug class | Local anesthetic |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Pain management |
| Phase | FDA-approved |
Mechanism of action
Lidocaine is a local anesthetic that penetrates the skin and underlying tissues to reversibly inhibit sodium influx through voltage-gated sodium channels in nociceptive nerve fibers. This prevents depolarization and propagation of action potentials, thereby reducing pain sensation in the treated area. The patch formulation provides sustained local delivery to minimize systemic absorption.
Approved indications
- Postherpetic neuralgia (PHN)
- Localized neuropathic pain
Common side effects
- Skin irritation or erythema at application site
- Contact dermatitis
- Mild burning or stinging at application site
Key clinical trials
- Pharmacokinetics and Adhesion of Lidocaine Topical System 1.8% Under Conditions of Heat and Exercise (PHASE1)
- Pharmacokinetic Study of Lidocaine Patch 1.8% Lidocaine Patch 5% (Lidoderm®) in Healthy Subjects (PHASE1)
- Adhesion Performance Study of Lidocaine Topical System 1.8% Compared to Generic Lidocaine Patch 5% in Healthy, Adult, Human Subjects (PHASE1)
- Diode Laser as a Biomarker for Neuropathic Pain of Peripheral Origin. (NA)
- Lidocaine Patch 1.8% for Moderate to Severe Pain From Carpal Tunnel Syndrome (PHASE4)
- Clinical Adhesion Study Between ZTlido 1.8% and Three Over-the-counter External Analgesic Lidocaine-containing Patches (PHASE1)
- Pharmacokinetics and Adhesion of Lidocaine Topical System 1.8% With Water Exposure (PHASE1)
- Adhesion Performance Study of Lidocaine Topical System 1.8% Compared to Lidocaine Patch 5% and Lidocaine Medicated Plaster 5% in Healthy, Adult, Human Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lidocaine patch 1.8% CI brief — competitive landscape report
- Lidocaine patch 1.8% updates RSS · CI watch RSS
- Scilex Pharmaceuticals, Inc. portfolio CI